Today's digest has 27 articles: first oral GLI1 PROTAC and a lead-optimized RET inhibitor in medchem, eight pharmacology papers from cIAP1 biology to sepsis, six computational preprints on benchmarks and active learning, and industry news led by Bayer's asundexian approval and the FDA's GLP-1 eye-risk label.
2026-11-09 · ⚗️RET kinase inhibitor (small molecule) · Journal of Medicinal Chemistry (ACS)
- Approved selective RET drugs lose effect when solvent-front G810C/R mutations emerge, so the authors ran a systematic SAR campaign starting from their earlier RET inhibitors.
- The resulting compound F73 stays potent against V804M gatekeeper and G810C/R variants, and blocks RET phosphorylation and downstream SHC signaling in mutant Ba/F3 cells.
- It triggers apoptosis and cell-cycle arrest dose-dependently in CCDC6-RET and G810R lines, and shows stronger antitumor activity than selpercatinib in a G810R xenograft.
💡 PointsBased on the abstractGatekeeper and solvent-front mutations demand different answers: V804M is a steric clash that selpercatinib already sidesteps, whereas G810C/R crowds the hinge-exit region where the solvent-exposed tail sits. I'd want kinome selectivity next, since compounds tuned for mutants often regain off-target hits like KDR or FGFR. Also check whether activity holds in a G810 plus V804 compound-mutant background.
Discovery of F73, a New Generation RET Inhibitor Overcoming RET Gatekeeper (V804M) and Solvent-Front (G810C/R) Mutations ↗
2026-11-09 · ⚗️CGRP receptor antagonist peptide (lipidated) · Journal of Medicinal Chemistry (ACS)
- A 10-residue CGRP receptor antagonist peptide was decorated with lipid groups of differing chain length and PEG linkers, plus N-terminal changes, to build a migraine lead.
- A C18 diacid lipid gave the longest mouse half-life, and serum stability rose with lipid size, but receptor antagonism weakened.
- A fast, low-cost, HPLC-based assay for peptide binding to human serum albumin was also introduced, avoiding the membrane-adsorption and degradation problems of equilibrium dialysis.
💡 PointsBased on the abstractPotency loss with bigger lipids smells like the tag is crowding the receptor's extracellular domain, where small peptide antagonists bind. Semaglutide-style C18 diacid with a spacer is the obvious benchmark, so I'd want the potency-versus-albumin-binding trade-off plotted per analog. Also check whether serum-shifted potency, not buffer potency, still supports the dosing.
Lipid-Modified CGRP Receptor Antagonists: Balancing Pharmacokinetic Improvement and Potency Loss ↗
2026-11-09 · ⚗️Antimicrobial peptide (bacterial membranes, LPS/LTA) · Journal of Medicinal Chemistry (ACS)
- Peptides were derived from the structure of M. tuberculosis adenylate kinase, which binds both LPS and LTA, to cover Gram-negative and Gram-positive bacteria.
- Non-natural residues, N-terminal C6 acylation and arginine extension gave lead YK-mAK-17, an amphipathic helix that disrupts membranes and virulence pathways.
- It was stable, showed little resistance development, and was active against CRAB and MRSA.
- In mouse septic shock models it improved survival and limited organ damage.
💡 PointsBased on the abstractCationic amphipathic helices with lipid tails always look good on killing curves, so my first question is the therapeutic window: hemolysis, mammalian cytotoxicity and serum or plasma binding decide whether this beats polymyxin-type chemotypes. Membrane-disrupting mechanisms also blur LPS/LTA recognition with plain charge-driven lysis. I'd test a scrambled or less-charged control and look at how the acyl chain and arginine count move toxicity.
Broad-Spectrum Antimicrobial Peptide Designed from the Mycobacterium tuberculosis Adenylate Kinase Structure, Inspired by Its LPS/LTA Dual Recognition ↗
2026-11-03 · ⚗️HDAC/proteasome dual-target small molecule · European Journal of Medicinal Chemistry (Elsevier)
- Starting from the earlier lead ZY-2, the foot pocket binder, linker and terminal aryl group were varied systematically to build a dual HDAC/proteasome series.
- Deprotecting hit X17 gave X26, which keeps strong proteasome inhibition and leans toward HDAC2 over HDAC1, with good selectivity against HDAC6 and HDAC8.
- X26 was far more potent than ZY-2 against cancer cells, notably triple-negative MDA-MB-231, suppressing colonies, triggering apoptosis and DAMP release linked to immunogenic cell death.
- In an MDA-MB-231 xenograft it beat ZY-2.
💡 PointsBased on the abstractDual HDAC/proteasome pharmacology is hard to attribute: with one scaffold hitting both, the xenograft win over ZY-2 could come from either arm or from synergy. I'd want matched single-target controls and a bortezomib plus HDAC inhibitor combination as the benchmark. I'd also confirm the HDAC2 lean holds in cells, and check exposure, since a freshly unmasked polar group often hurts PK.
Discovery and optimization of novel HDAC/proteasome dual inhibitors with antitumor activity in solid tumor models ↗
2026-11-02 · ⚗️CDK2 small-molecule inhibitors · European Journal of Medicinal Chemistry (Elsevier)
- Structure-guided design fed a roughly 1800-member triazole library made by copper-catalyzed click chemistry in 96-well plates, with no purification.
- Crude mixtures went straight into a competitive fluorescence polarization assay; two screening rounds picked out actives.
- The lead, LL-K2in10, inhibits CDK2 in binding and enzymatic assays, and a co-crystal structure shows multiple hydrogen bonds explaining the SAR.
- In OVCAR3 cells it showed target engagement, lower Rb phosphorylation, reduced viability and altered cell cycle.
💡 PointsBased on the abstractScreening crude click mixtures is fast, but residual copper, unreacted azide or alkyne and aggregators can fake or mask binding, so my first move would be resynthesizing and purifying the top hits to confirm potency. Then selectivity: CDK2 over CDK1 and CDK9 is where ATP-site chemotypes usually fail, so I'd want a kinase panel and a head-to-head against established aminopyrazole or purine scaffolds.
Direct-to-biology high-throughput optimization enables rapid hit-to-lead discovery of potent CDK2 inhibitors ↗
2026-10-31 · ⚗️GLI1 transcription factor / CRBN-recruiting PROTAC · European Journal of Medicinal Chemistry (Elsevier)
- Targets GLI1, the Hedgehog effector downstream of SMO, to reach tumors resistant to SMO inhibitors, using a new series of CRBN-recruiting PROTAC degraders.
- Lead LRG20 degrades GLI1 and GLI2 more than GLI3 in HT-29 colorectal cells, via the ubiquitin-proteasome system, sparing typical CRBN neo-substrates.
- It suppresses cell growth, shows oral exposure in vivo, and curbs HT-29 xenograft tumors without evident toxicity.
💡 PointsBased on the abstractA transcription factor with no pocket is a classic degrader use case, and sparing the usual CRBN neo-substrates is reassuring. But GLI1/GLI2 preference over GLI3 needs proteome-wide support, and I'd want a non-degrading CRBN-binder control to prove the effect isn't just pathway noise. Next check: activity in SMO-inhibitor-resistant models, plus ternary-complex cooperativity, since oral exposure for a large PROTAC is the real surprise.
Discovery of the first orally bioavailable GLI1 PROTAC for the treatment of colorectal cancer ↗
2026-10-29 · ⚗️GluN2B-selective NMDA receptor antagonist (small molecule) · European Journal of Medicinal Chemistry (Elsevier)
- Onfasprodil (MIJ821), a GluN2B-selective NMDAR antagonist in Phase 2 for treatment-resistant depression, is limited to IV infusion by weak pharmacokinetics.
- A new series was designed using ligand-receptor interaction insights to retain GluN2B inhibition while improving drug-like properties.
- Lead compound 33 is potent in vitro, enters the brain, and shows lower metabolic clearance and good oral exposure in mice.
- Oral dosing produced antidepressant-like effects in chronic social defeat stress and forced swim models.
💡 PointsBased on the abstractOral exposure is the right problem to attack, since ifenprodil-site chemotypes have long suffered from phenol glucuronidation and hERG liability, as traxoprodil's QT signal showed. Before getting excited I'd want hERG, alpha1-adrenergic and sigma off-target data on compound 33. Forced swim is a weak translational readout, so receptor occupancy at the antidepressant-like dose would tell me more.
Discovery of potent, selective, and orally bioavailable GluN2B-NMDA receptor antagonists for the treatment of depression ↗
2026-11-09 · 🧬cIAP1 BIR3 domain (small-molecule antagonist) · British Journal of Pharmacology
- A screen flagged vitamin E as a suppressor of cell death triggered by TNF-α plus SMAC mimetics.
- It competes for the BIR3 domain of cIAP1, so the protein is not degraded and the RIPK1-dependent death complex does not form; antioxidant activity is not responsible.
- Binding was supported by several biophysical and cellular target-engagement assays.
- In a mouse colitis model, vitamin E eased disease while preserving cIAP1.
💡 PointsBased on the abstractThe practical catch is interaction, not mechanism: if a dietary supplement can blunt a SMAC mimetic by occupying BIR3, patients on these agents are a real concern. Before trusting the colitis result, I'd want the dose and tissue exposure needed for cIAP1 engagement compared with what supplementation actually achieves, plus a non-binding tocopherol analog as a control.
α‐tocopherol (Vitamin E) inhibits second mitochondria‐derived activator of caspases (SMAC) mimetic‐induced cell death by directly targeting cIAP1 degradation ↗
2026-11-07 · 🧬Dual cathepsin L / coronavirus 3CL protease inhibitors (nortropinone scaffold) · ACS Pharmacology & Translational Science
- Structure-guided inhibitors built on a nortropinone scaffold target human cathepsin L, needed for viral entry, and the 3C-like proteases of SARS-CoV-2 and MERS-CoV.
- The compounds were non-cytotoxic and potent against all three enzymes, with the lead compound strongest against cathepsin L.
- The lead suppressed SARS-CoV-2 infection in cell culture with a wide safety margin.
- Co-crystal structures with both viral proteases confirmed the binding mode and guided optimization.
💡 PointsBased on the abstractDual targeting is attractive, but I'd want to know which enzyme actually drives the antiviral effect in cells. Without a cathepsin L knockout or a 3CLpro-resistant virus, it's unresolved. Host cathepsin L inhibition also raises off-target and tolerability questions that a cell-culture margin can't answer. Next step: in vivo PK and a comparison against established 3CLpro inhibitors.
Utilization of the Nortropinone Scaffold in the Structure-Guided Design of Potent Inhibitors of Human Cathepsin L and the Chymotrypsin-like Proteases of SARS-CoV-2 and MERS-CoV ↗
2026-11-07 · 🧬Mitochondrial respiratory chain Complex I (oral small molecule) · British Journal of Pharmacology
- OPB-111077, an oral first-in-class small molecule, inhibits mitochondrial Complex I and suppresses oxidative phosphorylation.
- It showed anti-tumour activity across haematological and solid tumour cell lines, cell-line xenografts and lymphoma patient-derived xenografts.
- Bendamustine pushed cancer cells toward an oxidative-phosphorylation-dependent state, which made them more sensitive to the inhibitor.
- The combination was synergistic, shutting down both oxidative phosphorylation and glycolysis.
💡 PointsBased on the abstractComplex I inhibitors have a hard history: on-target neurotoxicity and lactic acidosis narrowed the window in the clinic, so synergy in xenografts says little until we see exposure at the combination dose. The bendamustine-induced OXPHOS dependence is the interesting hook, but I'd want a rescue control (e.g. a yeast NDI1 bypass) to prove the effect is truly Complex I, plus tolerability data for the pair.
An inhibitor of the mitochondrial respiratory chain exerts synergistic anti‐tumour effects when combined with alkylating agents ↗
2026-11-07 · 🧬Triptonide (Tripterygium wilfordii diterpenoid) · British Journal of Pharmacology
- Triptonide, a diterpenoid from Tripterygium wilfordii, was tested in mouse endotoxemia and caecal ligation and puncture models of sepsis-associated lung injury.
- It limited macrophage pro-inflammatory activation, reduced lung inflammation, oedema and apoptosis, and improved survival.
- Transcriptomic and metabolic analyses showed suppressed aerobic glycolysis in inflammatory macrophages, via the STAT3/HIF-1α axis.
💡 PointsBased on the abstractTriptonide is a notoriously narrow-window Tripterygium compound, so I'd want the therapeutic index before any mechanism claim. Dosing after CLP onset, not just pre-treatment, plus a STAT3 or HIF-1α rescue to prove the axis is causal, would tell me far more. Glycolysis suppression in macrophages also risks blunting host defence against the infection itself.
Triptonide alleviates sepsis‐associated acute lung injury by suppressing the STAT3/HIF‐1α‐mediated aerobic glycolysis in macrophages ↗
2026-11-06 · 🧬Probenecid (transporter/pannexin-1 inhibitor) with cyclic nucleotide modulators · Biochemical Pharmacology
- Probenecid, known to block organic acid transporters, MRPs and pannexin-1, was tested on isolated pig detrusor muscle.
- It relaxed the tissue in a concentration-dependent but partial manner, and enhanced relaxation by cAMP- and cGMP-raising agents including a PDE5 inhibitor.
- The enhancement depended on the soluble guanylyl cyclase pathway, with higher intracellular and lower extracellular cGMP.
- Selective OAT, P2X7 and pannexin-1 tools did not reproduce the effect; PDE3A, PDE5 and MRP4 were found in bladder tissue.
💡 PointsBased on the abstractProbenecid is a dirty tool: it hits OAT, MRPs and pannexin-1, and the selective probes failed to copy the effect, so the mechanism is unassigned. MRP4 efflux blockade is the obvious suspect, which a clean MRP4 inhibitor or knockdown would test. Also unresolved: whether human detrusor and tolerable free exposure reproduce this.
Probenecid promotes relaxation and potentiates the effects of cyclic nucleotide-elevating agents in the pig detrusor ↗
2026-11-04 · 🧬AP-site-directed platinum(II) adduct-forming agent · Biochemical Pharmacology
- Benzoquinoplatin, a benzoquinoline carrying a monofunctional platinum(II) group, covalently traps abasic DNA sites so APE1 can no longer cleave them; the enzyme itself is not inhibited.
- In cancer cells it caused sustained DNA-damage signalling, cell cycle arrest and apoptosis, and was far more potent than cisplatin.
- It stayed active in cisplatin-resistant cells and slowed resistant xenograft growth.
- Combining it with PARP inhibition was synergistic.
💡 PointsBased on the abstractTrapping AP sites sidesteps the usual enzyme-inhibitor problem, but a monofunctional platinum adduct raises the selectivity question: what keeps it from reacting with other DNA sites, proteins or thiols? I'd want repair-deficient versus proficient isogenic pairs, normal-cell toxicity and some exposure data before believing the xenograft result. The PARP synergy is plausible, yet it may also add marrow toxicity.
Benzoquinoplatin, an Apurinic/Apyrimidinic site Adduct-Forming Agent, Disables APE1 repair and overcomes cancer chemoresistance ↗
2026-11-04 · 🧬CD99-targeted antibody-drug conjugate (doxorubicin payload) · Biochemical Pharmacology
- A hybridoma IgM antibody against CD99 was converted to a recombinant IgG2a format made in CHO cells, keeping its specific CD99 recognition.
- The antibody promoted cell death and curbed growth of CD99-positive Ewing sarcoma cells in vitro.
- Linked to doxorubicin, it localised to and was retained in A673 xenografts.
- The conjugate suppressed tumour growth more than vehicle or antibody alone, with more necrosis and lower proliferation in tumour tissue.
💡 PointsBased on the abstractCD99 is a credible Ewing target, but it is also expressed on normal haematopoietic and endothelial cells, so I want to see binding data on those before any enthusiasm. The missing control is a non-targeting IgG-doxorubicin conjugate: without it, A673 xenograft benefit could be plain payload delivery via leaky vasculature. Next step: free-doxorubicin comparison at matched dose, plus cardiac readouts.
A recombinant CD99-targeted antibody–drug conjugate for Ewing sarcoma therapy ↗
2026-11-04 · 🧬p97 ATPase inhibitor (CB-5083) · Biochemical Pharmacology
- Cigarette smoke raised p97 in lung epithelial cells while lowering SIRT1 and SUMO1, alongside higher inflammatory cytokine release.
- The p97 inhibitor CB-5083 reduced senescence and restored SIRT1 stability, activity and SUMO conjugation in these cells.
- A SUMOylation inhibitor, 2-D08, cancelled the protection in cells.
- In a mouse COPD model, CB-5083 lessened alveolar damage, neutrophil infiltration and cytokines, and 2-D08 reversed the benefit.
💡 PointsBased on the abstractp97 is a pan-essential ATPase in protein quality control, and CB-5083 was pulled from oncology trials over off-target toxicity, so the safety margin is my first worry for a chronic lung disease. 2-D08 reversing the benefit is nice, but it's a blunt SUMO-pathway inhibitor; I'd want SIRT1 knockdown or a SUMO-site mutant to prove the mechanism, plus inhaled delivery to limit systemic exposure.
p97 inhibition attenuates cigarette Smoke-Induced lung inflammation and epithelial senescence by Restoring SIRT1 SUMOylation ↗
2026-11-10 · 💻LLM-based systematic literature review and screening workflow · chemRxiv
- CESAR is an open-source workflow that builds a literature corpus by chasing references and citing papers through OpenAlex, then has LLMs screen abstracts, calibrated against human-annotated sets.
- Tested on a broad field (total synthesis) and a narrow target (MAGL), retrospectively against curated references; the corpus recovered most known papers and cheaper models came close to costly ones.
- An open-weight model run locally matched cloud results while also extracting selectivity and compound names, allowing confidential screening. Preprint, not peer reviewed.
💡 PointsBased on the abstractRecovering most known papers is a recall figure measured against curated lists that were probably built from the same literature and citation links, so it says little about what the chain misses. Before trusting it on your target, hand-screen a random sample of the rejected abstracts to estimate false negatives, since that is where a landscape quietly goes wrong.
Orchestrating literature landscaping in drug discovery by coupling citation expansion with large language models ↗
2026-11-10 · 💻Molecular property prediction (GNN with non-covalent graph and pharmacophore auxiliary task) · chemRxiv
- A graph neural network adds a second graph of hydrogen-bond and van der Waals contacts, kept only when chemical geometry rules are met, and trains with an auxiliary atom-level pharmacophore task.
- On several MoleculeNet classification sets with scaffold splits and no pretraining, it was competitive with or better than baselines, and the modules also helped another GNN.
- A small prospective logD check on newly measured compounds showed moderate error. This is a chemRxiv preprint, not peer reviewed.
💡 PointsBased on the abstractScaffold splits are the right choice, but I'd want the gain checked against a plain GNN with matched capacity and equal tuning, since a second graph and an auxiliary head add parameters. The pharmacophore labels are also rule-derived, so the model may just be relearning the rules. Try it on your own series, and judge the logD check against a simple baseline.
Chemistry-informed non-covalent graphs and pharmacophore supervision for molecular property prediction ↗
2026-11-10 · 💻Property prediction benchmarking for cyclic peptides (permeability, binding affinity, half-life) · chemRxiv
- A broad retrospective benchmark compares many model families and molecular representations on curated public cyclic-peptide data covering permeability, binding and half-life.
- Permeability is the most learnable endpoint; affinity and half-life stay hard. Tree ensembles do well for regression, pretrained chemical language models for classification, with no universal winner.
- Results depend heavily on split strategy, task framing and dataset makeup, and no-skill baselines are essential to read them. An open framework is released. Preprint, not peer reviewed.
💡 PointsBased on the abstractBefore trusting any cyclic peptide model, ask how the split was drawn. Random splits across near-identical scaffolds from one lab's series can flatter permeability scores, and that endpoint looks learnable partly because assays are consistent. For your own project, hold out whole chemical series, and compare against a no-skill baseline on your assay before committing synthesis effort.
Assessing the predictive limits of machine learning on cyclic peptides ↗
2026-11-10 · 💻Active-learning-guided virtual screening of ultra-large make-on-demand libraries · chemRxiv
- Preprint (not peer reviewed): an open-source Python package that treats the scoring oracle as a swappable function, so docking, free-energy calculations, stored scores or assay data can all feed one active-learning loop.
- It bundles many surrogate models, acquisition strategies and molecular featurizers, plus cycle scheduling, pruning and diversity tracking.
- Retrospective tests on precomputed docking scores for AmpC and D4 libraries of up to over a hundred million compounds show most top-scoring molecules are found after scoring only a small fraction, far beyond random picking.
- Smaller batches help recovery at higher cost; pruning cuts workload with a slight loss. No prospective validation is reported.
💡 PointsBased on the abstractRecovery on precomputed docking scores mostly shows the surrogate can learn the docking function, not that the hits are real binders, and AmpC and D4 are the familiar, well-behaved benchmarks. The test that matters for a team is a noisy oracle: run it on your own assay or FEP data, with a random-pick control and a scaffold-diversity check on what it recovers.
LearnM8: A Simple and Modular Molecular Active Learning Framework for any Oracle ↗
2026-11-10 · 💻Scaffold hopping (small-molecule core replacement) · chemRxiv
- Builds a benchmark from PDB ligand pairs sharing a pocket but differing in scaffold, scoring hops by how well reference protein contacts are conserved after crystal superposition, with no docking.
- SV-Hop combines a large core-replacement rule library, property and synthesizability filters, and a learned contact ranker.
- Evaluated retrospectively; it outperforms property-, 2D-similarity-based and random baselines, but the advantage shrinks markedly when whole targets are held out.
- A prospective compound panel is released. Preprint, not peer reviewed.
💡 PointsBased on the abstractThe held-out-target drop is the number to watch: PDB pairs sharing a pocket invite leakage, since a ranker can memorize contact patterns for familiar families. Contact conservation is also only a proxy; it says nothing about whether a hop keeps potency. Before trusting it, run it on our own series and compare synthesized hops against measured activity.
Scaffold hopping from deposited crystal pairs: docking-free contact-conservation benchmark and structure-validated method ↗
2026-11-09 · 💻Coordinate-based quality assessment of predicted protein structures · bioRxiv
- WhatRes is a coordinate-only assessment tool that places a structure on two axes: the experimental resolution its local geometry resembles, and how realistic that geometry is compared with experimental structures of similar resolution.
- It is applied to AI-predicted models and benchmarked against experimental structures, rather than tested prospectively on a design project.
- Even confidently predicted models can look high-resolution yet show noticeably narrower spread in bond lengths and angles than real high-resolution crystal structures, so they are over-idealised.
- This is a bioRxiv preprint and has not been peer reviewed.
💡 PointsBased on the abstractFlagging a narrow bond-length spread is easy; whether it matters for us is the open question. Deposited crystal geometry is itself shaped by refinement restraints, so the "realistic" reference is partly a refinement convention. Before trusting the score, check whether it tracks docking pose recovery or pocket accuracy on models of your own targets.
Realism and resolution: How AI-predicted protein structures differ from experimental structures ↗
2026-11-10 · 🏢Financing · BioPharma Dive · Oyster Therapeutics
- London-based Oyster Therapeutics (formerly Kesmalea Therapeutics) raised $60M in a Series A-2 extension led by 4BIO Capital, with eight other investors including Lilly.
- Its lead protein degrader links a tau-binding molecule to an enzyme-recruiting moiety; the company says it targets disease-causing tau while sparing healthy forms.
- A clinic start date has not been disclosed. Oyster is working with Massachusetts General Hospital on a neurotoxic tau form and is assessing cancer and immunology uses.
💡 PointsBased on public reportsTau has burned plenty of antibody programs, so a degrader aimed at only the pathological form is an intriguing alternative, yet this is preclinical-stage storytelling with no clinic date. Lilly's presence among the investors is the more telling signal; whether selectivity and brain exposure hold up in humans is the real test.
London biotech Oyster harvests $60M for tau-targeting brain drugs ↗
2026-11-09 · 🏢FDA approval · BioPharma Dive · Bayer
- FDA approved Bayer's once-daily oral Sunharbo (asundexian) on Nov. 9, the first Factor XIa inhibitor cleared, for adults with a prior warning stroke or non-cardiac clot-related stroke, alongside antiplatelet therapy.
- In a pivotal trial of 12,000+ adults, ischemic stroke risk fell 26% versus placebo with similar major bleeding; diarrhea was the most common adverse reaction.
- List price is $748.50 per 30 days; launch starts with stroke neurologists.
💡 PointsBased on public reportsFactor XIa has been the industry's great hope for bleeding-sparing anticoagulation, so a first approval matters, but this label is narrow: secondary stroke prevention on top of antiplatelets, not the AF market where Eliquis dominates. Watch how Bayer sequences further indications, and how Novartis and others' XIa programs respond.
Bayer wins FDA nod for a new kind of blood thinner ↗
2026-11-09 · 🏢Acquisition · BioSpace · CorMedix
- CorMedix agreed to acquire substantially all Heron Therapeutics assets for $145M in cash plus 14,583,333 CorMedix shares, with up to $55M in earn-outs tied to 2028 ZYNRELEF sales.
- The deal adds ZYNRELEF, APONVIE, CINVANTI and SUSTOL; CorMedix targets $45-60M in cost synergies and a $150M Pharmakon term loan.
- Closing is expected in Q1 2027, pending Heron stockholder approval and HSR clearance.
💡 PointsBased on public reportsThis moves CorMedix from a one-product story built on DefenCath into a broader hospital-focused commercial platform, with four products sold to the same institutional buyers. The earn-out tied to 2028 ZYNRELEF sales suggests the buyer is hedging on that product's uptake against entrenched competitors such as Exparel. The $45-60M synergy target and new term loan make integration execution the next test.
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care ↗
2026-11-09 · 🏢Regulatory · BioSpace · FDA / Novo Nordisk / Eli Lilly
- FDA is requiring all approved GLP-1 receptor agonists to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to Warnings and Precautions; indications are unchanged.
- Twelve products are affected, including Wegovy, Ozempic, Zepbound and Mounjaro.
- A trial meta-analysis found 6.4 NAION events per 100,000 patient-years with GLP-1s versus 3.8 for comparators; FDA found no mechanism in animal data.
💡 PointsBased on public reportsA Warnings-section addition rather than a boxed warning keeps the commercial hit modest, and the absolute difference is small. Still, class-wide wording denies Novo and Lilly any differentiation on eye safety. What's missing is mechanism and per-drug data; watch for ophthalmology-driven prescribing caution in high-risk patients.
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease ↗
2026-11-09 · 🏢Phase 3 readout · BioSpace · Johnson & Johnson / Protagonist Therapeutics
- Phase 3 ICONIC-PsA 1 met its primary endpoint: 58% of Icotyde patients reached ACR20 at week 16 versus 41% on placebo, with no new safety signals reported by J&J.
- BMO put placebo-adjusted joint improvement at 17% versus 23% for Skyrizi in KEEPsAKE 1, saying this does not establish differentiation.
- BMO sees oral convenience driving uptake and expects long-term share gains; Icotyde was approved for plaque psoriasis in March 2026.
💡 PointsBased on public reportsCross-trial comparisons are shaky, but a smaller placebo-adjusted gain than Skyrizi means Icotyde cannot win on joint efficacy. Its pitch is convenience: the first oral IL-23R peptide against an injectable incumbent. For J&J, which also sells Tremfya, the question is whether pill preference outweighs a visible efficacy gap.
J&J and Protagonist's Icotyde improves psoriatic arthritis but AbbVie's Skyrizi likely to reign ↗
2026-11-09 · 🏢Clinical readout · BioSpace · Boehringer Ingelheim / Zealand Pharma
- In the Phase 3 SYNCHRONIZE-CVOT trial (5,530 adults with overweight or obesity and elevated cardiovascular risk), survodutide was non-inferior to placebo on major cardiovascular events.
- Results were presented at AHA and published in The Lancet; at 72 weeks it also lowered systolic blood pressure and waist circumference versus placebo.
- GI-related discontinuations ran about 19-21% versus 1.9% on placebo; Zealand attributes this to limited titration flexibility, and analysts flag tolerability as a liability.
- The data support global regulatory filings for obesity.
💡 PointsBased on public reportsClearing the CV safety bar de-risks filing, but survodutide arrives behind semaglutide and tirzepatide with GI discontinuations near 20%, which is hard to defend commercially. Its real differentiation is glucagon-driven liver benefit; the MASH data and any gentler titration results will decide whether it is a contender or a follower.
Boehringer, Zealand's obesity drug doesn't elevate heart risk in key late-stage test ↗
